Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,458 total articles
KORU Medical (KRMD) looks repairable after a pullback to the low $3s. Healthy liquidity, improving technicals, low leverage and modest free cash flow give a base for a mid-term swing trade. This idea lays out an actionable entry at $3.70 with a $5.00 target and a $3.10 stop, plus what to watch to invalidate the thesis.
AutoNation is trading at roughly $180 with a P/E near 9 and EV/EBITDA ~8.5. The company has been aggressively buying back stock, driving per-share metrics higher even as top-line auto retail pressures show up in parts & service and new-vehicle margins. This trade idea buys the pullback for a mid-term run tied to continued buybacks and margin stabil…
Kamada is a cash-generating plasma-derived therapeutics company with improving profitability, recent FDA wins and low leverage. We are upgrading to Buy with a mid-term (45 trading days) trade plan: entry $8.10, target $9.50, stop $7.25. The setup balances near-term catalysts and operational expansion against legacy cash flow pressure and execution …
Synopsys (SNPS) combines recurring EDA revenues, accelerating Design IP momentum, and an Ansys-accretive product set. Valuation is premium but justified by free cash flow and near-term catalysts. I propose a mid-term long trade into the December earnings cadence with a defined entry, stop and target.
Cisco reported record fiscal Q1 results and raised FY27 guidance after a blowout quarter led by AI hyperscaler demand. The stock still offers upside to the $130 area while trading at a premium justified by accelerating networking and AI infrastructure revenue. We recommend a long trade with clear entry, stop and target tied to fundamentals and risk…
Core Scientific sits at the intersection of legacy bitcoin mining and a nascent hosting opportunity for GPU-driven AI workloads. Improving GPU supply from AMD and recent upward earnings revisions give the stock upside potential, but negative free cash flow, high implied valuations and execution risks warrant a conservative, core-sized long with a c…
Denali's first commercial win with Avlayah validated its TransportVehicle platform and unlocked near-term revenue growth. Q3 showed a clear commercial ramp and management guided $30-32M for Q4. The company still carries pipeline binary risk and high burn, but with roughly $1.08B in cash and a market cap near $3.03B, this is a buy for investors who …
Suncor reported a clean Q3 beat on both revenue and EPS, and the stock has pulled back into technical support after a strong YTD run. With refining cash flow intact, a modest dividend yield and a P/E near 10, the risk/reward favors a tactical long over the next 45 trading days. Entry, stop and target provided for a disciplined trade.
Accenture ($ACN) benefits from an undeniable AI-led tailwind that has driven an 18-27% run in recent weeks, but valuation, stretched short-term technicals, and a compressed margin runway make the stock vulnerable to a pullback. This trade idea advocates a mid-term short with precise entry, stop and target levels and a clear set of catalysts and ris…
Kimbell Royalty Partners (KRP) combines a high 10%+ yield with production growth and recent $367M of acquisitions that are already proving accretive. At roughly $16.20 and a market cap near $2.2B, KRP looks undervalued relative to its cash flow generation and modest leverage. This trade idea outlines a long position with a $20.40 target over a 180‑…
CytomX (CTMX) is a clinical-stage oncology biotech with a masked antibody platform that's underappreciated after a messy sell-off. The company has non-dilutive collaboration payments and a $250M equity raise behind it, a meaningful short interest base, and upcoming clinical readouts that can re-rate the stock. This is a mid-term swing trade: enter …
Celestica (CLS) has dropped sharply from its summer highs but the fundamental setup looks intact: outsized AI/data-center demand, accelerating revenue and margin expansion, strong cash flow and a clean balance sheet. This trade idea lays out a clear entry, stop and target with time horizon and risks spelled out.
Lumen (LUMN) looks like a turnaround that the market has overly punished. Strategic revenue now represents the majority of sales, management has reiterated guidance, and valuation is cheap on multiple fronts. This trade targets a mid-term rebound while protecting downside with a defined stop.
Banco do Brasil has been punished by back-to-back sell-offs tied to political headlines and macro stress. The bank's core retail deposit franchise and state-backed footprint remain intact; at roughly 0.2x book the upside looks compelling. We upgrade to Buy with a clear entry, stop and target for a long-term trade.
Bank of Montreal (BMO) combines consistent earnings momentum with a durable retail footprint, a 2.8% yield and a valuation that still offers upside toward the 52-week high. We lay out a long trade with entry, target and stop, a 180-trading-day horizon, and clear risk triggers.
Maze (MAZE) is a clinical-stage, genetics-first small-molecule biotech focused on renal and CVRM diseases. The stock is trading around $36 with bullish technical momentum and elevated analyst targets; the trade here is a directional long that prices optionality around partnering/outsourcing of commercialization and late-stage development.
ANPMF trades at a fraction of its 52-week peak, offers a low PE and modest PB, and carries a high short-interest profile. We favor a long exposure sized for a long-duration trade: entry $3.20, stop $2.90, target $5.50 over ~180 trading days, with clear triggers to reassess.
Fortrea reported a clean Q3 beat, is capturing oncology and precision-medicine demand, and trades at a reasonable price-to-free-cash-flow multiple despite elevated leverage. This trade targets a mid-term rebound to prior highs while keeping risk tight to guard against macro or client pacing weakness.
monday.com (MNDY) reported a Q3 beat with $377.5M revenue and $2.14 EPS, and management highlighted $36M ARR from AI products plus a 37% increase in enterprise accounts above $100k ARR. The stock sits at $76.95 with a $3.25B market cap and a trailing P/E near 26.7. We view an actionable long: entry $76.95, stop $65.00, target $110.00 over a long-te…
CF Industries (CF) is a cash-generative, low-leverage nitrogen fertilizer producer trading at attractive multiples. Recent operational disruptions have tightened supply and created a window for price resilience. We like a long entry at $125.00 with a $150.00 target over the next 180 trading days and a $108.00 stop to manage downside.
Magnite's CTV growth and margin expansion are real and visible in recent results, but the stock is trading at premium multiples with overbought technicals. For traders, a defined short-swing (mid-term) offers asymmetric risk-reward: entry at the current price, tight stop above the breakout, and a target down near the 50-day moving average and prior…
Diodes Inc. (DIOD) looks like a buyable dip. Recent weakness has more to do with sector-wide derating and heavy short activity than with the company's underlying results. With a market cap near $4.19B, positive free cash flow ($123.62M), improving technicals and an acquisition that adds higher-margin revenue, DIOD warrants a tactical long: entry $9…
Cognizant (CTSH) has faced investor worry that AI-era competition will compress consulting and implementation margins. Recent quarter results and the balance sheet argue otherwise: Cognizant beat Q3 top- and bottom-line expectations, generates meaningful free cash flow, and trades at a low-teens P/E. We think near-term pricing pressure is manageabl…
Leidos beat Q3 EPS and raised 2026 EPS and cash-flow guidance while trimming revenue targets. The fundamentals - free cash flow of $1.96B, a modest P/E and an EV/EBITDA near 9 - argue for a mid-term long trade on weakness. Entry, stop and target defined for a 45-trading-day swing that captures Homeland momentum while respecting execution risk in He…
Ashland reported a modest Q4 miss but gave FY2027 guidance that implies better EBITDA and cash conversion. The balance sheet is healthy, free cash flow is strong ($237M), and a $1B buyback plus a renewed dividend provide a constructive capital-allocation backdrop. This trade idea takes a long stance to capture operational improvement and potential …
